Literature DB >> 11088040

Adenovirus-mediated glial cell line-derived neurotrophic factor gene delivery reduces motor neuron injury after transient spinal cord ischemia in rabbits.

M Sakurai1, K Abe, T Hayashi, Y Setoguchi, G Yaginuma, T Meguro, K Tabayashi.   

Abstract

OBJECTIVE: Glial cell line-derived neurotrophic factor (GDNF) has protective effects on various injuries involving the central and peripheral nervous systems in vitro and vivo. However, the possible protective effect of GDNF on spinal cord ischemia and the exact mechanism involved in the ameliorative effect of GDNF on ischemic spinal cord injuries are not fully understood. Therefore, we investigated the possible protective effect of the adenovirus-mediated GDNF gene delivery on transient spinal cord ischemia in rabbits.
METHODS: The adenoviral vector (lacZ gene as a control or GDNF gene contained) was injected directly into the lumbar spinal cord via a needle inserted into the dorsal spine 2 days before the animal was subjected to 15 minutes of spinal cord ischemia induced by infrarenal aortic occlusion. In situ terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick-end labeling (TUNEL staining) was performed, and temporal profiles of the GDNF and caspase-3 (caspase-3 is the marker of apoptotic change) immunoreactivity were investigated.
RESULTS: In the control rabbit, the majority of motor neurons showed selective cell death at 7 days of reperfusion. Immunocytochemistry showed that in situ TUNEL staining was selectively detected at 2 days of reperfusion in motor neuron nuclei. GDNF and caspase-3 were selectively induced in the motor neuron cells at 8 hours of reperfusion. In the GDNF-treated group, a large population of motor neuron cells was still surviving at 7 days after having been subjected to 15 minutes of ischemia. Unlike the control group, the GDNF-treated group expressed GDNF persistently. Induction of TUNEL staining and immunoreactivity for caspase-3 were greatly reduced by the GDNF treatment.
CONCLUSION: These results suggest that the reduction in motor neuron death by GDNF was greatly associated with a reduction in DNA fragmentation and apoptotic signals of the caspase-3 cascade; they further suggest a great potential for gene therapy for paraplegic patients in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11088040     DOI: 10.1067/mtc.2000.111178

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

Review 1.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

2.  Adenoviral vector carrying glial cell-derived neurotrophic factor for direct gene therapy in comparison with human umbilical cord blood cell-mediated therapy of spinal cord injury in rat.

Authors:  Y O Mukhamedshina; G F Shaymardanova; Е Е Garanina; I I Salafutdinov; А А Rizvanov; R R Islamov; Y A Chelyshev
Journal:  Spinal Cord       Date:  2015-09-29       Impact factor: 2.772

Review 3.  Gene delivery with viral vectors for cerebrovascular diseases.

Authors:  Yu Gan; Zheng Jing; Ruth Anne Stetler; Guodong Cao
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01

4.  Overexpression of Brain- and Glial Cell Line-Derived Neurotrophic Factors Is Neuroprotective in an Animal Model of Acute Hypobaric Hypoxia.

Authors:  Maria S Gavrish; Mark D Urazov; Tatiana A Mishchenko; Victoria D Turubanova; Ekaterina A Epifanova; Victoria G Krut'; Alexey A Babaev; Maria V Vedunova; Elena V Mitroshina
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

5.  Glial Cell Line-derived Neurotrophic Factor-overexpressing Human Neural Stem/Progenitor Cells Enhance Therapeutic Efficiency in Rat with Traumatic Spinal Cord Injury.

Authors:  Kyujin Hwang; Kwangsoo Jung; Il-Sun Kim; Miri Kim; Jungho Han; Joohee Lim; Jeong Eun Shin; Jae-Hyung Jang; Kook In Park
Journal:  Exp Neurobiol       Date:  2019-12-31       Impact factor: 3.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.